164 related articles for article (PubMed ID: 22761439)
1. Chemically programmed bispecific antibodies that recruit and activate T cells.
Cui H; Thomas JD; Burke TR; Rader C
J Biol Chem; 2012 Aug; 287(34):28206-14. PubMed ID: 22761439
[TBL] [Abstract][Full Text] [Related]
2. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.
Qi J; Hymel D; Nelson CG; Burke TR; Rader C
Front Immunol; 2019; 10():1994. PubMed ID: 31497024
[TBL] [Abstract][Full Text] [Related]
3. Chemically Programmed Bispecific Antibodies in Diabody Format.
Walseng E; Nelson CG; Qi J; Nanna AR; Roush WR; Goswami RK; Sinha SC; Burke TR; Rader C
J Biol Chem; 2016 Sep; 291(37):19661-73. PubMed ID: 27445334
[TBL] [Abstract][Full Text] [Related]
4. Redirecting cytotoxic T cells with chemically programmed antibodies.
Qi J; Rader C
Bioorg Med Chem; 2020 Dec; 28(24):115834. PubMed ID: 33166926
[TBL] [Abstract][Full Text] [Related]
5. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Geiger M; Stubenrauch KG; Sam J; Richter WF; Jordan G; Eckmann J; Hage C; Nicolini V; Freimoser-Grundschober A; Ritter M; Lauer ME; Stahlberg H; Ringler P; Patel J; Sullivan E; Grau-Richards S; Endres S; Kobold S; Umaña P; Brünker P; Klein C
Nat Commun; 2020 Jun; 11(1):3196. PubMed ID: 32581215
[TBL] [Abstract][Full Text] [Related]
6. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
7. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
[TBL] [Abstract][Full Text] [Related]
10. Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.
Meng W; Tang A; Ye X; Gui X; Li L; Fan X; Schultz RD; Freed DC; Ha S; Wang D; Zhang N; Fu TM; An Z
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038280
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
[TBL] [Abstract][Full Text] [Related]
12. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a Novel Bispecific Antibody That Activates T Cells
Chornoguz O; Leettola CN; Leander K; Brosnan K; Emmell E; Chiu ML; Santulli-Marotto S
Monoclon Antib Immunodiagn Immunother; 2019 Dec; 38(6):242-254. PubMed ID: 31825302
[TBL] [Abstract][Full Text] [Related]
14. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies.
Brinkmann U; Kontermann RE
Science; 2021 May; 372(6545):916-917. PubMed ID: 34045345
[No Abstract] [Full Text] [Related]
16. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of monospecific and bispecific hexavalent trimerbodies.
Blanco-Toribio A; Sainz-Pastor N; Álvarez-Cienfuegos A; Merino N; Cuesta ÁM; Sánchez-Martín D; Bonet J; Santos-Valle P; Sanz L; Oliva B; Blanco FJ; Álvarez-Vallina L
MAbs; 2013; 5(1):70-9. PubMed ID: 23221741
[TBL] [Abstract][Full Text] [Related]
18. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
19. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
20. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
